Suppr超能文献

炎症血浆生物标志物与组织病理学病变、肾脏疾病进展及死亡率的关联——波士顿肾脏活检队列研究

The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.

作者信息

Srivastava Anand, Schmidt Insa M, Palsson Ragnar, Weins Astrid, Bonventre Joseph V, Sabbisetti Venkata, Stillman Isaac E, Rennke Helmut G, Waikar Sushrut S

机构信息

Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Section of Nephrology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.

出版信息

Kidney Int Rep. 2021 Jan 6;6(3):685-694. doi: 10.1016/j.ekir.2020.12.025. eCollection 2021 Mar.

Abstract

BACKGROUND

Soluble tumor necrosis factor receptor (sTNFR)-1, sTNFR-2, YKL-40, monocyte chemoattractant protein (MCP)-1, and soluble urokinase plasminogen activator receptor (suPAR) have emerged as promising biomarkers of inflammation but have not been evaluated across diverse types of kidney diseases.

METHODS

We measured these plasma biomarkers in 523 individuals enrolled into a prospective, observational cohort study of patients undergoing clinically indicated native kidney biopsy at 3 tertiary care hospitals. Two kidney pathologists adjudicated biopsy specimens for semiquantitative scores of histopathology. Proportional hazard models tested associations between biomarkers and risks of kidney disease progression (composite of ≥40% estimated glomerular filtration rate [eGFR] decline or end-stage kidney disease [ESKD]) and death.

RESULTS

Mean eGFR was 56.4±36 ml/min per 1.73 m and the median proteinuria (interquartile range) was 1.6 (0.4, 3.9) g/g creatinine. The most common primary clinicopathologic diagnoses were proliferative glomerulonephritis (29.2%), nonproliferative glomerulopathy (18.1%), advanced glomerulosclerosis (11.3%), and diabetic kidney disease (11.1%). sTNFR-1, sTNFR-2, MCP-1, and suPAR were associated with tubulointerstitial and glomerular lesions. YKL-40 was not associated with any histopathologic lesions after multivariable adjustment. During a median follow-up of 65 months, 182 participants suffered kidney disease progression and 85 participants died. After multivariable adjustment, each doubling of sTNFR-1, sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of kidney disease progression, with hazard ratios ranging from 1.21 to 1.47. Each doubling of sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of death, with hazard ratios ranging from 1.33 to 1.45. suPAR was not significantly associated with kidney disease progression or death.

CONCLUSIONS

sTNFR-1, sTNFR-2, YKL-40, MCP-1, and suPAR are associated with underlying histopathologic lesions and adverse clinical outcomes across a diverse set of kidney diseases.

摘要

背景

可溶性肿瘤坏死因子受体(sTNFR)-1、sTNFR-2、YKL-40、单核细胞趋化蛋白(MCP)-1和可溶性尿激酶型纤溶酶原激活物受体(suPAR)已成为很有前景的炎症生物标志物,但尚未在多种类型的肾脏疾病中进行评估。

方法

我们在523名个体中测量了这些血浆生物标志物,这些个体参与了一项前瞻性观察队列研究,该研究纳入了3家三级医疗机构中接受临床指征的自体肾活检的患者。两名肾脏病理学家对活检标本进行组织病理学半定量评分。比例风险模型测试了生物标志物与肾脏疾病进展风险(估计肾小球滤过率[eGFR]下降≥40%或终末期肾病[ESKD]的综合情况)和死亡风险之间的关联。

结果

平均eGFR为每1.73平方米56.4±36 ml/min,蛋白尿中位数(四分位间距)为1.6(0.4,3.9)g/g肌酐。最常见的原发性临床病理诊断为增殖性肾小球肾炎(29.2%)、非增殖性肾小球病(18.1%)、晚期肾小球硬化(11.3%)和糖尿病肾病(11.1%)。sTNFR-1、sTNFR-2、MCP-1和suPAR与肾小管间质和肾小球病变相关。多变量调整后,YKL-40与任何组织病理学病变均无关联。在中位随访65个月期间,182名参与者出现肾脏疾病进展,85名参与者死亡。多变量调整后,sTNFR-1、sTNFR-2、YKL-40和MCP-1每增加一倍,肾脏疾病进展风险增加,风险比范围为1.21至1.47。sTNFR-2、YKL-40和MCP-1每增加一倍,死亡风险增加,风险比范围为1.33至1.45。suPAR与肾脏疾病进展或死亡无显著关联。

结论

sTNFR-1、sTNFR-2、YKL-40、MCP-1和suPAR与多种肾脏疾病的潜在组织病理学病变及不良临床结局相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e783/7938082/f398c2b466a9/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验